VKTX - Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
2024-04-24 13:02:30 ET
Summary
- Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH.
- The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Pharmaceuticals and one it should have exclusive access to for some years.
- However, to maintain its "first mover" advantage, the company has to launch the drug effectively and keep an eye on future competitors.
- We take a more detailed look at Madrigal Pharmaceuticals and the challenges ahead in the paragraphs below.
Today, we put mid-cap concern Madrigal Pharmaceuticals, Inc. ( MDGL ) in the spotlight. The company's lead candidate resmetirom (known by the brand name Rezdiffra) garnered the first FDA approval for a liver condition called nonalcoholic steatohepatitis, or NASH, in March. To the relief of the company and its investors, approval was granted without requiring a liver biopsy to confirm patients' eligibility for the pill, which had been a previous potential challenge....
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage